| Patent application number | Description | Published |
|---|
| 20090012272 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 01-08-2009 |
| 20090022744 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 01-22-2009 |
| 20090041768 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 02-12-2009 |
| 20090234104 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 09-17-2009 |
| 20090286964 | Modified Fc molecules - The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. | 11-19-2009 |
| Patent application number | Description | Published |
|---|
| 20080206184 | Chemically Modified Protein Compositions and Methods - The present invention broadly relates to the field of protein modification and more specifically, water soluble block polymers, their attachment to drugs, and methods of making and use thereof. | 08-28-2008 |
| 20090048149 | Antagonists of the bradykinin B1 receptor - The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor. | 02-19-2009 |
| 20090137452 | Antagonists of the bradykinin B1 receptor - The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor. | 05-28-2009 |
| 20090137483 | Antagonists of the bradykinin B1 receptor - The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor. | 05-28-2009 |
| 20110045587 | TOXIN PEPTIDE THERAPEUTIC AGENTS - Disclosed is a DNA encoding a composition of matter of the formula | 02-24-2011 |
